4BASEBIO PLC EO 1
4basebio PLC, together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally. The company offers hpDNA, double stranded linear DNA, covalently closed with single strand hairpins at the 5' and 3' ends for viral and non-viral vector applicat… Read more
Market Cap & Net Worth: 4BASEBIO PLC EO 1 (88Q)
4BASEBIO PLC EO 1 (F:88Q) has a market capitalization of $95.37 Million (€92.91 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #23295 globally and #2541 in its home market, demonstrating a -1.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 4BASEBIO PLC EO 1's stock price €6.00 by its total outstanding shares 15484875 (15.48 Million).
4BASEBIO PLC EO 1 Market Cap History: 2021 to 2026
4BASEBIO PLC EO 1's market capitalization history from 2021 to 2026. Data shows growth from $109.67 Million to $95.37 Million (12.99% CAGR).
4BASEBIO PLC EO 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 4BASEBIO PLC EO 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 88Q by Market Capitalization
Companies near 4BASEBIO PLC EO 1 in the global market cap rankings as of March 19, 2026.
Key companies related to 4BASEBIO PLC EO 1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
4BASEBIO PLC EO 1 Historical Marketcap From 2021 to 2026
Between 2021 and today, 4BASEBIO PLC EO 1's market cap moved from $109.67 Million to $ 95.37 Million, with a yearly change of 12.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €95.37 Million | -5.51% |
| 2025 | €100.93 Million | -55.59% |
| 2024 | €227.30 Million | +82.17% |
| 2023 | €124.77 Million | +1.29% |
| 2022 | €123.18 Million | +12.32% |
| 2021 | €109.67 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of 4BASEBIO PLC EO 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $95.37 Million USD |
| MoneyControl | $95.37 Million USD |
| MarketWatch | $95.37 Million USD |
| marketcap.company | $95.37 Million USD |
| Reuters | $95.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.